Skip to main content
  • Paul Armistead, MD, PhD

    Paul Armistead Becomes New Director of UNC’s Bone Marrow Transplant and Cellular Therapy Program

    Paul Michael Armistead MD, PhD, an associate professor of medicine and the associate chief of basic and translational research in the Division of Hematology is the new Director of UNC’s Bone Marrow Transplant and Cellular Therapy Program. Dr. Armistead came to North Carolina from Britain in 1985. He enrolled as an undergraduate at UNC Chapel Hill in 1991 receiving the prestigious … Read more

  • July- Grants and Funding

    Department of Medicine Grants & Funding: July 1 – July 31, 2022

    Division of Hematology Patrick Ellsworth, MD, received a grant for his project titled “Mechanistic Investigation of Factor IX/Ixa Synergy with Emicizumab” from Novo Nordisk “Access to Insight” Division of Nephrology and Hypertension Gang Xi, PhD, and Prabir Roy-Chaudhury, MD, PhD, FRCP(Edin), were recently awarded a $2.7 million grant by the National Institute of Diabetes and Dig … Read more

  • UNC School of Medicine Physician Scientists Training Program Gives Awards to Cultivate the Careers of Upcoming Physician-Scientists

    Medicine, like any other scientific field, cannot progress forward without the hard work of new, cutting-edge researchers. In the Department of Medicine, three physician scientist trainees are working to improve the lives of patients who have inflammatory bowel disease, cancer, and food allergies. In light of their promising, hard work, all three have received support from the UN … Read more

  • Stephan Moll, MD

    Dr. Stephan Moll Working with NASA to Study Blood Flow, Clot Formation in Zero Gravity

    Are astronauts more likely to develop blood clots during space missions due to zero gravity? That’s the question NASA is trying to answer with help from UNC School of Medicine’s Stephan Moll, MD, professor in the Division of Hematology within the UNC Department of Medicine. A new publication in Vascular Medicine shows the results of an occupational surveillance program spurred by … Read more

  • Shakira-Grant-directory

    Dr. Shakira J. Grant selected for PRIDE, hopes to encourage others to find their purpose

    As an assistant professor in the Divisions of Hematology and Geriatric Medicine, and a board-certified Geriatric-Hematologist, Dr. Shakira J. Grant, MBBS, is no stranger to success, but she has had to overcome many challenges along the way. Now, selected for the 2022 Programs to Increase Diversity Among Individuals Engaged in Health-Related Research (PRIDE) cohort, she hopes this … Read more

  • April- Grants and Funding

    epartment of Medicine Grants & Funding: April 1 – April 30, 2022

    Division of Hematology Nigel Key, MB, ChB, FRCP has been awarded a 5-year, $2.2M T32 grant from the National Heart, Lung and Blood Institute (NHLBI) Brandi Reeves, MD was awarded a 2-year, $165,000 Hemostasis and Thrombosis Research Society Mentored Research Award to study Hypoxia Inducible Factors in Myeloproliferative Neoplasm-Associated Thrombosis. Rafal Pawlinksi, PhD and Bra … Read more

  • March- Grants and Funding

    Department of Medicine Grants & Funding: March 1 – March 31, 2022

    Division of Oncology Yara Abdou, MD, received a METAvivor research grant for “Investigating Survivin as a novel target for immunotherapy in Black women with breast cancer.” Jared Weiss, MD, and Barbara Savoldo, MD, received a $1.8M DoD grant to study GD2 CART for lung lancer. Emily Ray, MD, received a 2-year $150,000 Career Development Award from the Lung Cancer Initiative for a … Read more

  • hem-covid-team-stitting

    DVT Awareness Month: Spotlighting Hematology Trial That Serves COVID Patients, BRC’s Thrombosis Related Research

    March is Deep-Vein Thrombosis (DVT) Awareness Month, a public health initiative that seeks to aid understanding of a commonly occurring and potentially life-threatening medical condition among the general population. DVT is commonly referred to as a blood clot (thrombus) that forms in one or more veins located deep inside the body. Did you know, almost one in four people don’t kn … Read more

  • Nigel Key, MB, ChB, FRCP

    Key awarded a 5-year, $2.2 million T32 grant from NHLBI

    Nigel Key, MB, ChB, FRCP has been awarded a 5-year, $2.2 million T32 grant from the National Heart, Lung, and Blood Institute (NHLBI). Now closely aligned with the benign hematology research areas of focus in the Blood Research Center (hemostasis, thrombosis and sickle cell disease), the program will continue to recruit MD and PhD trainees for careers in clinical and basic scienc … Read more

  • meier-vincent-serody-downs-canner-BCells-immunology-review

    B Cell Function in the Tumor Microenvironment, a Review in Advance, Annual Review of Immunology

    Jeremy Meier, MD, fellow in the division of hematology, Benjamin G. Vincent, MD, assistant professor in hematology, and Jonathan S. Serody, MD, chief of the division of hematology, are authors of the review “B Cell Function in the Tumor Microenvironment,” soon to be published in the Annual Review of Immunology. First author is Stephanie M. Downs-Canner, MD, assistant professor in … Read more

  • Coombs-leukemia-management-article

    Clinical Challenges: Using MRD in Chronic Lymphocytic Leukemia Management

    For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has correlated with time-to-event outcomes. Use of MRD has shown promise for guiding duration of treatment for CLL patients on time-limited therapy. “MRD measurement is not necessarily standard o … Read more

  • Alice-ma-new-approaches-hemophilia-treatment

    New Approaches to Hemophilia Treatment: ‘Our Cup Runneth Over’

    In a session titled “Hemophilia Update: Our Cup Runneth Over,” presented at the 2021 annual meeting of the American Society of Hematology (ASH), experts in the treatment of bleeding disorders discussed the optimal use of factor concentrates in people with hemophilia, new and investigational alternatives to factor concentrates, and the promise of long-time control or even cure wit … Read more